Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBC Conditioning for Auto-SCT in CNS Lymphoma
NCT06625359Phase 2Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2015
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, busulfan and cyclophosphamide in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Seoul National University Hospital. Primary endpoint: Progression-free survival at 1 year. Started Jun 2015; status: terminated.
02
Drugs
thiotepabusulfancyclophosphamide
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT06625359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625359.